Beset by drug failures and limited late-stage pipelines, big pharmaceutical companies are increasingly looking outside their own walls for scientific discoveries by partnering with academic institutions.
GlaxoSmithKline last July entered into a five-year, $25m deal with Harvard to support stem-cell research, particularly in the areas of heart disease and cancer.
